John C. Martin, the chief executive officer of Gilead Sciences Inc., has become a billionaire on the prospects of a powerful new hepatitis C drug that’s attracting scrutiny from payers and activists over its $1,000 per pill price tag.
Sanofi-Aventis SA made a takeover approach to Genzyme Corp. , the largest maker of medicines for genetic diseases, about two weeks ago, said two people with knowledge of the matter.
Harris Corp. a maker of communications-related electronic equipment, sued Netgear Inc. for allegedly infringing network-security patents.
Dendreon Corp. rose the most in a year on optimism that more patients will begin taking the biotechnology company’s prostate cancer drug Provenge.
Amgen Inc., the world’s largest biotechnology company, agreed to buy Micromet Inc. in a $1.16 billion deal to gain an experimental leukemia drug.
Vertex Pharmaceuticals Inc. rose in New York trading after its hepatitis C drug made treatment quicker and more effective in a study that may lead to $1.8 billion in annual U.S. sales.
Merck & Co. won a U.S. panel’s backing to sell an experimental hepatitis C drug that cured more patients in clinical trials than current therapies.
Dendreon Corp. rose after winning the backing of European Union regulators for the prostate cancer treatment Provenge, the company’s only marketed product.
Vertex Pharmaceuticals Inc. rose 12 percent in intraday trading after U.S. regulators said the company’s experimental hepatitis C drug cures more patients than current therapies.
GlaxoSmithKline Plc and Human Genome Sciences Inc. won a U.S. panel’s backing to sell the first new lupus drug in more than 50 years. Human Genome’s shares jumped 9.5 percent in extended trading.
"It was a brilliant transaction."
- Geoffrey Porges on Mar 02, 2014